Table 4 Grade 3–4 acute adverse events in 272 patients with stage III NPC
Variables | IMRT (N = 82) | CCRT (N = 190) | P |
|---|---|---|---|
Hematological | |||
Leukopenia | 1 (1.2%) | 22 (11.6%) | 0.005 |
Neutropenia | 0 (0.0%) | 14 (7.4%) | 0.012 |
Anemia | 0 (0.0%) | 4 (2.1%) | 0.186 |
Thrombocytopenia | 0 (0.0%) | 9 (4.8%) | 0.045 |
Non-hematological | |||
Mucositis | 16 (19.5%) | 96 (50.5%) | < 0.001 |
Xerostomia | 0 (0.0%) | 4 (2.1%) | 0.186 |
Dermatitis | 3 (3.7) | 6 (3.2%) | 0.833 |
Nausea/vomiting | 0 (0.0%) | 5 (2.6%) | 0.139 |
Hepatoxicity | 1 (1.2%) | 0 (0.0%) | 0.128 |